Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Iparomlimab and Tuvonralimab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07289997
What this trial is testing

Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)

Who this might be right for
AFP Gastric or Gastroesophageal Junction AdenocarcinomaPD-1/CTLA-4AFPGC+1 more
Hebei Medical University Fourth Hospital 39
Post-approval studies (Phase 4)Not Yet RecruitingNCT07004335
What this trial is testing

Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

Who this might be right for
PD-(L)1CTLA-4Advanced Melanoma+3 more
Hebei Medical University Fourth Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT07082179
What this trial is testing

A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Jiangsu Cancer Institute & Hospital 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07383285
What this trial is testing

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

Who this might be right for
Rectal Neoplasms Malignant
Peking University Cancer Hospital & Institute 106
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07156682
What this trial is testing

QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer

Who this might be right for
Colon CancerMSS/pMMRQL1706
Qilu Hospital of Shandong University 21
Not applicableNot Yet RecruitingNCT07538193
What this trial is testing

Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung (NSCLC)Neoplasm StagingLymphatic Metastasis
Tang-Du Hospital 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07151209
What this trial is testing

Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 20
Testing effectiveness (Phase 2)Looking for participantsNCT07290010
What this trial is testing

The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07139041
What this trial is testing

Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC

Who this might be right for
NSCLC (Non-small-cell Lung Cancer)
Chang Chen 69
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07197697
What this trial is testing

A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients

Who this might be right for
Breast Cancer
Anhui Provincial Cancer Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07134413
What this trial is testing

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

Who this might be right for
NSCLC
Guangdong Association of Clinical Trials 77
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07277972
What this trial is testing

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

Who this might be right for
RCC, Renal Cell Cancer
Tianjin Medical University Cancer Institute and Hospital 36
Testing effectiveness (Phase 2)Looking for participantsNCT07055399
What this trial is testing

Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)

Who this might be right for
Locally Advanced Cervical Cancer
Fujian Cancer Hospital 43
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06884982
What this trial is testing

An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib

Who this might be right for
HCC - Hepatocellular Carcinoma
Northern Jiangsu People's Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07369986
What this trial is testing

Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer

Who this might be right for
Endometrial CancerImmunotherapyMismatch Repair Deficiency
Women's Hospital School Of Medicine Zhejiang University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07148427
What this trial is testing

Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07009145
What this trial is testing

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

Who this might be right for
Unresectable Colorectal CancerMetastatic Colorectal Cancer (CRC)MSI-H/dMMR Colorectal Cancer
Qianfoshan Hospital 22
Testing effectiveness (Phase 2)Looking for participantsNCT07062055
What this trial is testing

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Who this might be right for
Hepatocellular CarcinomaPortal Vein Tumor ThrombusOligometastases+3 more
Shandong Cancer Hospital and Institute 54
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07263360
What this trial is testing

Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Who this might be right for
BTC
Tianjin Medical University Cancer Institute and Hospital 29
Testing effectiveness (Phase 2)Looking for participantsNCT06864013
What this trial is testing

SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer

Who this might be right for
Locally Advanced Rectal Cancer (LARC)
First Affiliated Hospital of Zhejiang University 116
Next Page